Sugi Predict

Sugi Predict / Compounds / SCHEMBL2014685

SCHEMBL2014685

SCHEMBL2014685

FC(F)c1ccnc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ SMARCA2 P51531 2/20 0.37
▸ IDH1 O75874 3/20 0.36
▸ IDH2 P48735 2/20 0.36
▸ RXRA P19793 4/20 0.34
▸ GRIN1 Q05586 4/20 0.34
▸ GRIN2B Q13224 4/20 0.34
▸ RPS6KA5 O75582 1/20 0.32
▸ SMARCA4 P51532 1/20 0.31
▸ GABRA1 P14867 1/20 0.30
▸ GABRG2 P18507 1/20 0.30
▸ GABRB3 P28472 1/20 0.30
▸ GABRA3 P34903 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013406 0.83 MAPK9 (0.37) TGFBR1MAPK9MAPK10RPS6KA5
SCHEMBL558541 0.77 MAPK9 (0.39) MAPK9MAPK10RXRAGRIN1GRIN2B
SCHEMBL2012670 0.77 MAPK9 (0.34) MAPK9MAPK10IDH1IDH2RPS6KA5
SCHEMBL27523149 0.76 MAPK9 (0.38) MAPK9MAPK10RPS6KA5
SCHEMBL3298801 0.74 IDH1 (0.37) SMARCA2IDH1IDH2RXRAGRIN1
SCHEMBL28404695 0.74 MAPK9 (0.37) MAPK9MAPK10RPS6KA5
SCHEMBL20858109 0.74 MAPK9 (0.37) MAPK9MAPK10RPS6KA5
SCHEMBL22065924 0.74 MAPK9 (0.37) MAPK9MAPK10RPS6KA5
SCHEMBL2018148 0.74 MAPK9 (0.37) MAPK9MAPK10RPS6KA5
SCHEMBL3407351 0.74 MAPK9 (0.33) MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026041663-A1 P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2026-02-26 — — WO disclosed
EP-4620955-A1 MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2025-09-24 — — EP disclosed
EP-3980412-B1 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2025-08-13 — — EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 — — US disclosed
CN-120202199-A MC4R antagonist compound, pharmaceutical composition and application thereof in medicine 长春金赛药业有限责任公司 2025-06-24 — — CN disclosed
US-12319671-B2 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2025-06-03 — — US disclosed
US-12257247-B2 Targeted degradation of VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-03-25 — — US disclosed
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 — — EP disclosed
US-20240317725-A1 LPA1 SMALL MOLECULE ANTAGONIST TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) 2024-09-26 — — US disclosed
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2024-08-29 — — US disclosed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 — — EP disclosed
EP-2513098-A1 AMINOPYRIMIDINES AS SYK INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-24 — — EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 — — US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 — — US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 — — US disclosed
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2011-10-06 — — US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 — — WO disclosed
WO-2011075517-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-06-23 — — WO disclosed
WO-2011075515-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-06-23 — — WO disclosed
CN-1473155-A Pyrimidine derivatives and herbicides containing the same ס������ũҩ��ʽ���� 2004-02-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 TGFBR1 1546/4885MAPK9 457/4885MAPK10 524/4885
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK TGFBR1 2278/4885MAPK9 956/4885MAPK10 1865/4885
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL TGFBR1 1920/4885MAPK9 777/4885MAPK10 572/4885
US-12257247-B2 Targeted degradation of VAV1 VAV1, KRAS, CBL TGFBR1 1920/4885MAPK9 777/4885MAPK10 572/4885
US-12319671-B2 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, BRSK2 TGFBR1 1488/4885MAPK9 322/4885MAPK10 628/4885
US-20240317725-A1 LPA1 SMALL MOLECULE ANTAGONIST LPAR1, LPAR2, LPAR4 TGFBR1 778/4885MAPK9 905/4885MAPK10 1320/4885
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL TGFBR1 1920/4885MAPK9 777/4885MAPK10 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.